

**IN THE CLAIMS**

This listing of the claims replaces all prior versions of the claims in the application.

1-22. (canceled)

23. (withdrawn -- currently amended): A method of activating T cells which recognize an epitope of an HCV polypeptide, comprising the step of:

contacting T cells with the composition of claim 5 45, whereby a population of activated T cells recognizes an epitope of the NS3, NS4, NS5a, or NS5b polypeptides.

24. (withdrawn): The method of claim 23 wherein the T cells are obtained from a mammal selected from the group consisting of a mouse, a baboon, a chimpanzee, and a human.

25. (withdrawn): The method of claim 24 wherein the mammal is infected with an HCV.

26. (withdrawn): The method of claim 24 wherein the mammal is not infected with an HCV.

27. (withdrawn): The method of claim 23 wherein the population of T cells comprises CD4<sup>+</sup> T cells.

28. (withdrawn): The method of claim 23 wherein the population of T cells comprises CD8<sup>+</sup> T cells.

29. (withdrawn): The method of claim 28 wherein the CD8<sup>+</sup> T cells express interferon- $\gamma$ .

30. (withdrawn): The method of claim 28 wherein the CD8<sup>+</sup> T cells specifically recognize an epitope of an NS5a polypeptide.

31. (withdrawn): The method of claim 30 wherein the epitope is selected from the group consisting of the epitopes shown in SEQ ID NO:1 and SEQ ID NO:2.

32. (withdrawn): The method of claim 23 wherein the T cells comprise CD8<sup>+</sup> and CD4<sup>+</sup> T cells.

33-36. (canceled)

37. (withdrawn): The method of claim 23 wherein the T cells are in a mammal.

38. (withdrawn): The method of claim 37 wherein the mammal is selected from the group consisting of a mouse, a baboon, a chimpanzee, and a human.

39. (withdrawn): The method of claim 37 wherein the mammal is infected with an HCV.

40. (withdrawn): The method of claim 37 wherein the mammal is not infected with an HCV.

41. (canceled)

42. (withdrawn -- currently amended): A method of activating T cells which recognize an epitope of an HCV polypeptide, comprising the step of:

contacting T cells with a composition according to claim 8 46, whereby a population of activated T cells recognizes an epitope of the NS3, NS4, NS5a, or NS5b polypeptides.

43-44. (canceled)

45. (currently amended): An immunogenic composition that activates HCV-specific T cells, said composition comprising HCV polypeptides, wherein the HCV polypeptides consist of:

- (a) an isolated and purified NS3 polypeptide of a hepatitis C virus (HCV);
- (b) an isolated and purified NS4 polypeptide of a HCV;
- (c) an isolated and purified NS5a polypeptide of a HCV;
- (d) an isolated and purified NS5b polypeptide of a HCV;
- (e) an isolated and purified core polypeptide of a HCV;
- (f) a pharmaceutically acceptable excipient; and
- (g) an adjuvant,

wherein one of the HCV polypeptides is from a different strain of HCV than the other HCV polypeptides, and wherein each of the HCV polypeptides is provided individually.

46. (currently amended): An immunogenic composition that activates HCV-specific T cells, said composition comprising HCV polypeptides, wherein the HCV polypeptides consist of:

- (a) an isolated and purified NS3 polypeptide of a hepatitis C virus (HCV);
- (b) an isolated and purified NS4 polypeptide of a HCV;
- (c) an isolated and purified NS5a polypeptide of a HCV;
- (d) an isolated and purified NS5b polypeptide of a HCV;
- (e) an isolated and purified core polypeptide of a HCV;
- (f) a pharmaceutically acceptable excipient; and
- (g) an adjuvant,

wherein each of the HCV polypeptides is from a different strain of HCV, and wherein each of the HCV polypeptides is provided individually.